Analysed WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) News Sources
WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer
29-12-2025
yahoo.com
WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026
29-12-2025
yahoo.com
WORK Medical Deepens Web3.0 Strategic Layout: Co-authors Asset Tokenization Whitepaper
01-05-2026
yahoo.com
WORK Medical Collaborates with Novabioplus to Unlock Biological Data Value with AI, Advancing the “BioToken” Assetization Model
11-05-2026
yahoo.com
AI Healthcare and BioToken Partnership Expands WORK Medical’s (WOK) Digital Asset Ambitions
11-05-2026
advfn.com
WORK Medical Technology Group Is Trending Overnight — Here's Why WOK Stock Surged Over 69% In After-Hours Session
13-05-2026
yahoo.com
WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
03-06-2026
yahoo.com
What is the current price of WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ)?
The current price of WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) is $0.0458.
WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) absolute price change since previous trading day?
The absolute price change of WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) since the previous trading day is $-0.0049.
WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) percentage price change since previous trading day?
The percentage price change of WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) since the previous trading day is -9.6647%.
What is the most recent average sentiment score for WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ)?
The most recent average sentiment score for WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ)?
The most recent sentiment for WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ) is .
SEC-8K** Filing Available For WORK MEDICAL TECHNOLOGY GR-A (WOK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.